Some analysts warn of biotech bubble

05/28/2013 | Reuters

Shares in biologic-drug companies are at all-time highs, leading some analysts to issue cautions. A favorable regulatory environment, lower interest rates, advances in genetics and interest from general fund managers have helped drive the Nasdaq Biotech Index up 45% over last year's averages. "There are exciting new opportunities, but you also need to be careful because most drugs fail," said Rajiv Kaul, a biotech portfolio manager at Fidelity Investments.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT